Attributable mortality of nosocomial candidemia, revisited.

We reexamined the attributable mortality of nosocomial candidemia 15 years after a retrospective cohort study performed at our hospital demonstrated an attributable mortality of 38%. For all episodes of nosocomial candidemia between 1 July 1997 and 30 June 2001, we matched control patients with case patients by age, sex, date of hospital admission, underlying disease(s), length of time at risk, and surgical procedure(s). We analyzed 108 matched pairs. There were no statistically significant differences in age, sex, underlying disease(s), time at risk, surgical procedure, or vital signs at admission between cases and controls. The crude mortality among case patients was 61% (66 of 108 patients), compared with 12% (13 of 108) among control patients, for an attributable mortality of 49% (95% CI, 38%-60%). Nosocomial candidemia is still associated with an extremely high crude and attributable mortality--much higher than that expected from underlying disease alone.

[1]  D. McClish,et al.  Nosocomial bloodstream infections in United States hospitals: a three-year analysis. , 1999, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[2]  G. Parmigiani,et al.  The clinical significance of positive blood cultures in the 1990s: a prospective comprehensive evaluation of the microbiology, epidemiology, and outcome of bacteremia and fungemia in adults. , 1997, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[3]  R. Wenzel,et al.  Vancomycin-resistant enterococcal bacteremia: natural history and attributable mortality. , 1996, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[4]  M. Levenstein,et al.  Efficacy and safety of fluconazole prophylaxis for fungal infections after marrow transplantation--a prospective, randomized, double-blind study. , 1995, The Journal of infectious diseases.

[5]  Nnis System,et al.  National Nosocomial Infections Surveillance (NNIS) System Report, Data Summary from January 1990-May 1999, issued June 1999. A report from the NNIS System. , 1999, American journal of infection control.

[6]  Jonathan R. Edwards,et al.  and the National Nosocomial Infections Surveillance System Hospitals , 2002 .

[7]  R F Woolson,et al.  Hospital-acquired candidemia. The attributable mortality and excess length of stay. , 1988, Archives of internal medicine.

[8]  B. Plikaytis,et al.  Trends in mortality due to invasive mycotic diseases in the United States, 1980-1997. , 2001, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[9]  ohn,et al.  COMPARISON OF CASPOFUNGIN AND AMPHOTERICIN B FOR INVASIVE CANDIDIASIS , 2002 .

[10]  R. Gaynes,et al.  Secular trend of hospital-acquired candidemia among intensive care unit patients in the United States during 1989-1999. , 2002, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[11]  D. Snydman,et al.  Attributable mortality of Stenotrophomonas maltophilia bacteremia. , 2002, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[12]  Nnis System.  National Nosocomial Infections Surveillance (NNIS) System Report, data summary from January 1992 through June 2003, issued August 2003. , 2003, American journal of infection control.

[13]  Jeanne E. Zack,et al.  Effect of an education program on decreasing catheter-related bloodstream infections in the surgical intensive care unit , 2002, Critical care medicine.

[14]  J. Myers,et al.  Nosocomial fungemia in a large community teaching hospital. , 1987, Archives of internal medicine.

[15]  J. Sobel,et al.  Fungemia caused by Candida species and Torulopsis glabrata in the hospitalized patient: frequency, characteristics, and evaluation of factors influencing outcome. , 1989, Reviews of infectious diseases.

[16]  Prolonged fluconazole prophylaxis is associated with persistent protection against candidiasis-related death in allogeneic marrow transplant recipients: long-term follow-up of a randomized, placebo-controlled trial. , 2000 .

[17]  J. Sobel,et al.  Practice guidelines for the treatment of candidiasis. Infectious Diseases Society of America. , 2000, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[18]  J. Enders,et al.  Infectious Diseases Society of America. , 1969, Antimicrobial agents and chemotherapy.

[19]  M. Pfaller,et al.  Role of Sentinel Surveillance of Candidemia: Trends in Species Distribution and Antifungal Susceptibility , 2002, Journal of Clinical Microbiology.

[20]  A. Macías.  Impact of Nosocomial Infections on Outcome Myths and Evidence , 2000, Infection Control & Hospital Epidemiology.

[21]  A. Callow,et al.  Candida Infections in Surgical Patients , 1983, Annals of surgery.

[22]  D. Snydman,et al.  Attributable mortality of bacteremia associated with the Bacteroides fragilis group. , 1995, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[23]  J. Sobel,et al.  Invasive candidiasis: turning risk into a practical prevention policy? , 2001, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[24]  R. Wenzel,et al.  Coagulase-negative staphylococcal bacteremia. Mortality and hospital stay , 1990 .

[25]  D. Pittet,et al.  Nosocomial bloodstream infection in critically ill patients. Excess length of stay, extra costs, and attributable mortality. , 1994, JAMA.

[26]  M. Levenstein,et al.  A Randomized Trial Comparing Fluconazole with Amphotericin B for the Treatment of Candidemia in Patients without Neutropenia , 1994 .

[27]  B. Wong,et al.  Fungemia in a cancer hospital: changing frequency, earlier onset, and results of therapy. , 1985, Reviews of infectious diseases.

[28]  W. Kreisel,et al.  A randomized, double-blind, double-dummy, multicenter trial of voriconazole and fluconazole in the treatment of esophageal candidiasis in immunocompromised patients. , 2001, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[29]  C. Watanakunakorn,et al.  Hospital-acquired fungemia. Its natural course and clinical significance. , 1979, The American journal of medicine.

[30]  C. Mackenzie,et al.  A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. , 1987, Journal of chronic diseases.

[31]  D. Pittet,et al.  Microbiological factors influencing the outcome of nosocomial bloodstream infections: a 6-year validated, population-based model. , 1997, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[32]  J. Sobel,et al.  Practice guidelines for the treatment of candidiasis. Infectious Diseases Society of America. , 2000, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[33]  V. Fraser,et al.  Candidemia in a tertiary care hospital: epidemiology, risk factors, and predictors of mortality. , 1992, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.